Press Releases Keyword Search Year None20232022202120202019201820172016201520142013 06/01/23 Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference DUBLIN, Ireland , June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio... 05/31/23 Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023 – 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growi... 05/04/23 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results -- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate fo... 05/03/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN , May 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focus... 05/01/23 Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy - Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; ... 04/20/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 04/10/23 Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference DUBLIN, Ireland , April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi... 04/03/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN , April 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company foc... 03/30/23 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results • LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to ... 03/29/23 Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30 DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi... 03/29/23 Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: ... 03/29/23 Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: ... 03/29/23 Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million – In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic ... 03/22/23 Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision Importation of LUMRYZ to the U.S. shortens the time to product availability following a final approv... 03/21/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , March 21, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/02/23 Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension - Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland ... 02/16/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Feb. 16, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 02/08/23 Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference DUBLIN, Ireland , Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio... 02/03/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Feb. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 01/24/23 Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates - Adverse events were reported in patients who took the second, middle-of-the-night dose of immediat... 01/23/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Jan. 23, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 01/10/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
06/01/23 Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference DUBLIN, Ireland , June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
05/31/23 Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023 – 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growi...
05/04/23 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results -- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate fo...
05/03/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN , May 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focus...
05/01/23 Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy - Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; ...
04/20/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
04/10/23 Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference DUBLIN, Ireland , April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
04/03/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN , April 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company foc...
03/30/23 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results • LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to ...
03/29/23 Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30 DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
03/29/23 Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: ...
03/29/23 Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: ...
03/29/23 Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million – In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic ...
03/22/23 Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision Importation of LUMRYZ to the U.S. shortens the time to product availability following a final approv...
03/21/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , March 21, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/02/23 Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension - Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland ...
02/16/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Feb. 16, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
02/08/23 Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference DUBLIN, Ireland , Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
02/03/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Feb. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
01/24/23 Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates - Adverse events were reported in patients who took the second, middle-of-the-night dose of immediat...
01/23/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Jan. 23, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
01/10/23 Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
